Interpace Diagnostics Group Stock Price, News & Analysis (NASDAQ:IDXG)

$1.05 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.05
Today's Range$1.00 - $1.07
52-Week Range$0.72 - $4.45
Volume931,191 shs
Average Volume451,490 shs
Market Capitalization$28.19 million
P/E Ratio0.35
Dividend YieldN/A
Beta1.64

About Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group logoInterpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Business Support Services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:IDXG
CUSIP69329V10
Phone844-405-9655

Debt

Debt-to-Equity RatioN/A
Current Ratio1.90%
Quick Ratio1.90%

Price-To-Earnings

Trailing P/E Ratio0.351170568561873
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.09 million
Price / Sales2.15
Cash FlowN/A
Price / CashN/A
Book Value$2.33 per share
Price / Book0.45

Profitability

Trailing EPS$2.99
Net Income$-8,330,000.00
Net Margins-6.33%
Return on Equity-5.69%
Return on Assets-3.06%

Miscellaneous

Employees61
Outstanding Shares26,850,000

Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) released its earnings results on Thursday, August, 10th. The business services provider reported ($0.65) EPS for the quarter. The business services provider earned $3.86 million during the quarter. Interpace Diagnostics Group had a negative return on equity of 5.69% and a negative net margin of 6.33%. View Interpace Diagnostics Group's Earnings History.

Where is Interpace Diagnostics Group's stock going? Where will Interpace Diagnostics Group's stock price be in 2018?

2 brokers have issued 1-year target prices for Interpace Diagnostics Group's shares. Their forecasts range from $3.00 to $4.50. On average, they anticipate Interpace Diagnostics Group's stock price to reach $3.75 in the next twelve months. View Analyst Ratings for Interpace Diagnostics Group.

Who are some of Interpace Diagnostics Group's key competitors?

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the folowing people:

  • Stephen J. Sullivan, Chairman of the Board (Age 70)
  • Jack E. Stover CPA, President, Chief Executive Officer, Director (Age 64)
  • James Early, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer (Age 63)
  • Felice Schnoll-Sussman, Director
  • Joseph D. Keegan Ph.D., Independent Director (Age 62)

Who owns Interpace Diagnostics Group stock?

Interpace Diagnostics Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sabby Management LLC (4.91%) and Virtu Financial LLC (0.49%). View Institutional Ownership Trends for Interpace Diagnostics Group.

Who bought Interpace Diagnostics Group stock? Who is buying Interpace Diagnostics Group stock?

Interpace Diagnostics Group's stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC and Virtu Financial LLC. View Insider Buying and Selling for Interpace Diagnostics Group.

How do I buy Interpace Diagnostics Group stock?

Shares of Interpace Diagnostics Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of Interpace Diagnostics Group stock can currently be purchased for approximately $1.05.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $28.19 million and generates $13.09 million in revenue each year. The business services provider earns $-8,330,000.00 in net income (profit) each year or $2.99 on an earnings per share basis. Interpace Diagnostics Group employs 61 workers across the globe.

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING A 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 844-405-9655 or via email at [email protected]


MarketBeat Community Rating for Interpace Diagnostics Group (IDXG)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Interpace Diagnostics Group (NASDAQ:IDXG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.75$5.00$5.00$5.00
Price Target Upside: 303.23% upside290.63% upside290.63% upside504.23% upside

Interpace Diagnostics Group (NASDAQ:IDXG) Consensus Price Target History

Price Target History for Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group (NASDAQ:IDXG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018LaidlawInitiated CoverageBuy -> Buy$4.50HighView Rating Details
2/14/2018Maxim GroupReiterated RatingBuy -> Buy$5.00 -> $3.00MediumView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Interpace Diagnostics Group (NASDAQ:IDXG) Earnings History and Estimates Chart

Earnings by Quarter for Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group (NASDAQ IDXG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.15)$4.20 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.65)$3.86 millionViewN/AView Earnings Details
5/15/2017Q1 2017$0.42$3.47 millionViewN/AView Earnings Details
3/29/2017Q4 2016$3.25$3.12 millionViewN/AView Earnings Details
11/18/2016Q3 2016($4.00)$3.32 millionViewN/AView Earnings Details
8/16/2016Q2 2016($1.90)$3.61 millionViewN/AView Earnings Details
5/12/2016Q1 2016($2.30)$3.04 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.31)$32.35 million$36.60 millionViewListenView Earnings Details
8/13/2015Q215($0.46)($0.44)$32.62 million$34.10 millionViewListenView Earnings Details
5/12/2015Q115($0.48)($0.25)$33.20 million$38.30 millionViewListenView Earnings Details
3/3/2015Q414($0.50)($0.27)$140.87 million$28.90 millionViewListenView Earnings Details
11/3/2014Q3($0.19)($0.29)$33.40 million$29.20 millionViewListenView Earnings Details
8/13/2014Q2($0.12)($0.17)$35.60 million$31.60 millionViewListenView Earnings Details
5/7/2014Q1($0.11)($0.11)$39.48 million$32.80 millionViewListenView Earnings Details
2/27/2014Q4($0.11)($0.25)$38.09 million$36.41 millionViewListenView Earnings Details
11/12/2013Q3($0.23)($0.14)$37.98 million$34.26 millionViewListenView Earnings Details
8/5/2013Q2 2013($0.11)($0.06)$35.26 million$37.20 millionViewListenView Earnings Details
5/13/2013Q1 2013($1.10)$1.40$38.02 million$42.92 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.07)($1.64)$36.90 million$35.60 millionViewListenView Earnings Details
11/5/2012Q3 2012($0.40)($0.60)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.70)($0.27)ViewN/AView Earnings Details
5/14/2012Q1 2012$0.20($0.21)ViewN/AView Earnings Details
3/7/2012Q4 2011($0.40)($0.01)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.60)($0.13)ViewN/AView Earnings Details
8/8/2011Q2 2011($1.10)($0.61)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.90)($0.37)ViewN/AView Earnings Details
3/21/2011Q4 2010$0.20($1.17)ViewN/AView Earnings Details
11/3/2010Q3 2010($1.10)$0.28ViewN/AView Earnings Details
8/4/2010Q2 2010($2.00)($0.62)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.90)($1.19)ViewN/AView Earnings Details
3/4/2010Q4 2009($1.80)($0.99)ViewN/AView Earnings Details
11/5/2009Q3 2009($3.50)($3.21)ViewN/AView Earnings Details
8/5/2009Q2 2009($4.00)($3.40)ViewN/AView Earnings Details
5/6/2009Q1 2009($4.00)ViewN/AView Earnings Details
3/11/2009Q4 2008($7.00)($12.03)ViewN/AView Earnings Details
11/6/2008Q3 2008($6.42)ViewN/AView Earnings Details
8/6/2008Q2 2008($5.30)ViewN/AView Earnings Details
5/8/2008Q1 2008($1.70)($0.76)ViewN/AView Earnings Details
3/12/2008Q4 2007($1.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Interpace Diagnostics Group (NASDAQ:IDXG) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Interpace Diagnostics Group (NASDAQ:IDXG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Interpace Diagnostics Group (NASDAQ IDXG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.70%
Institutional Ownership Percentage: 6.75%
Insider Trades by Quarter for Interpace Diagnostics Group (NASDAQ:IDXG)
Institutional Ownership by Quarter for Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group (NASDAQ IDXG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/25/2014Graham G MiaoCFOBuy22,000$1.65$36,300.00View SEC Filing  
11/10/2014Nancy LurkerCEOBuy49,000$1.75$85,750.00View SEC Filing  
11/7/2014Gerald R Melillo JrInsiderBuy5,000$1.58$7,900.00View SEC Filing  
11/7/2014Jeffrey Edward SmithVPBuy200,000$1.75$350,000.00View SEC Filing  
11/6/2014Nancy LurkerCEOBuy57,000$1.74$99,180.00View SEC Filing  
11/5/2014Gerald P BelleDirectorBuy57,300$1.71$97,983.00View SEC Filing  
11/18/2013Gerald BelleDirectorBuy20,400$5.21$106,284.0084,357View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Interpace Diagnostics Group (NASDAQ IDXG) News Headlines

Source:
DateHeadline
Interpace Diagnostics CEO Interviewed on The RedChip Money ... - GlobeNewswire (press release)Interpace Diagnostics' CEO Interviewed on The RedChip Money ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 8:16 AM
Interpace Diagnostics Group (IDXG) Research Coverage Started at LaidlawInterpace Diagnostics Group (IDXG) Research Coverage Started at Laidlaw
www.americanbankingnews.com - February 22 at 3:02 PM
Interpace Diagnostics Group Inc (IDXG) PT Lowered to $3 at Maxim Group - StreetInsider.comInterpace Diagnostics Group Inc (IDXG) PT Lowered to $3 at Maxim Group - StreetInsider.com
www.streetinsider.com - February 16 at 8:14 AM
Interpace Diagnostics Group (IDXG) Given a $3.00 Price Target by Maxim Group AnalystsInterpace Diagnostics Group (IDXG) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - February 14 at 10:40 PM
Interpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung AssaysInterpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung Assays
finance.yahoo.com - February 12 at 9:07 AM
Analyzing MAXIMUS (MMS) & Interpace Diagnostics Group (IDXG)Analyzing MAXIMUS (MMS) & Interpace Diagnostics Group (IDXG)
www.americanbankingnews.com - January 26 at 9:06 AM
Interpace Diagnostics to Present at NobleCon14 on January 29Interpace Diagnostics to Present at NobleCon14 on January 29
finance.yahoo.com - January 25 at 9:05 AM
Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers - GlobeNewswire (press release)Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers - GlobeNewswire (press release)
globenewswire.com - January 8 at 4:00 PM
What Does Interpace Diagnostics Group Inc’s (NASDAQ:IDXG) Share Price Indicate?What Does Interpace Diagnostics Group Inc’s (NASDAQ:IDXG) Share Price Indicate?
finance.yahoo.com - January 6 at 6:30 AM
Comparing Interpace Diagnostics Group (IDXG) & Lifelock (LOCK)Comparing Interpace Diagnostics Group (IDXG) & Lifelock (LOCK)
www.americanbankingnews.com - December 28 at 7:34 PM
Interpace Diagnostics Announces Agreement with ARUP Laboratories - GlobeNewswire (press release)Interpace Diagnostics Announces Agreement with ARUP Laboratories - GlobeNewswire (press release)
globenewswire.com - December 19 at 3:53 PM
Interpace Diagnostics Group (IDXG) and Willdan Group (WLDN) Financial SurveyInterpace Diagnostics Group (IDXG) and Willdan Group (WLDN) Financial Survey
www.americanbankingnews.com - December 19 at 1:26 AM
Interpace Diagnostics Group, Inc. :IDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017Interpace Diagnostics Group, Inc. :IDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017
finance.yahoo.com - December 18 at 11:37 AM
Contrasting Interpace Diagnostics Group (IDXG) & Ritchie Bros. Auctioneers (RBA)Contrasting Interpace Diagnostics Group (IDXG) & Ritchie Bros. Auctioneers (RBA)
www.americanbankingnews.com - November 24 at 3:28 AM
Head-To-Head Analysis: Unifirst Corporation (UNF) versus Interpace Diagnostics Group (IDXG)Head-To-Head Analysis: Unifirst Corporation (UNF) versus Interpace Diagnostics Group (IDXG)
www.americanbankingnews.com - November 18 at 3:37 AM
BRIEF-Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offeringBRIEF-Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering
www.reuters.com - November 17 at 6:40 PM
Interpace Diagnostics Announces New York State Approval of New ProductInterpace Diagnostics Announces New York State Approval of New Product
finance.yahoo.com - November 17 at 5:36 AM
Interpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim GroupInterpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim Group
www.americanbankingnews.com - November 14 at 1:14 PM
BRIEF-Interpace Diagnostics says Q3 sales up 27 pctBRIEF-Interpace Diagnostics says Q3 sales up 27 pct
www.reuters.com - November 14 at 12:51 AM
Edited Transcript of IDXG earnings conference call or presentation 13-Nov-17 1:30pm GMTEdited Transcript of IDXG earnings conference call or presentation 13-Nov-17 1:30pm GMT
finance.yahoo.com - November 14 at 12:51 AM
Interpace Diagnostics Groups (IDXG) CEO Jack Stover on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaInterpace Diagnostics Group's (IDXG) CEO Jack Stover on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 13 at 7:49 PM
Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent AccomplishmentsInterpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments
finance.yahoo.com - November 13 at 7:49 PM
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017
finance.yahoo.com - November 11 at 11:14 AM
Ituran Location and Control (ITRN) & Interpace Diagnostics Group (IDXG) Financial ContrastIturan Location and Control (ITRN) & Interpace Diagnostics Group (IDXG) Financial Contrast
www.americanbankingnews.com - November 7 at 9:36 PM
Recent VRSK NewsRecent VRSK News
www.bloomberg.com - November 2 at 1:52 AM
Todays Research Report Coverage on Business Services Stocks -- Interpace Diagnostics, ITUS Corp., Marathon Patent, and Verisk AnalyticsToday's Research Report Coverage on Business Services Stocks -- Interpace Diagnostics, ITUS Corp., Marathon Patent, and Verisk Analytics
www.prnewswire.com - October 30 at 9:47 PM
NetworkNewsBreaks - VistaGen Therapeutics, Inc. VTGN Shares Surge on FDA Authorization to Commence Phase 2 Study of AV-101 for MDDNetworkNewsBreaks - VistaGen Therapeutics, Inc. VTGN Shares Surge on FDA Authorization to Commence Phase 2 Study of AV-101 for MDD
www.marketwatch.com - October 26 at 12:52 PM
Interpace Diagnostics Designated as “Company of the Month” by G2 IntelligenceInterpace Diagnostics Designated as “Company of the Month” by G2 Intelligence
finance.yahoo.com - October 26 at 12:52 PM
Interpace Diagnostics Presents Important Data at the World Congress of Gastroenterology at American College of ... - GlobeNewswire (press release)Interpace Diagnostics Presents Important Data at the World Congress of Gastroenterology at American College of ... - GlobeNewswire (press release)
globenewswire.com - October 23 at 9:26 PM
Interpace Diagnostics Presents Important Data at the World Congress of Gastroenterology at American College of Gastroenterology (ACG) 2017Interpace Diagnostics Presents Important Data at the World Congress of Gastroenterology at American College of Gastroenterology (ACG) 2017
finance.yahoo.com - October 23 at 4:26 PM
Interpace Diagnostics Presents New Data from Over 3,400 Patients Tested with ThyGenX®/ThyraMIR®Interpace Diagnostics Presents New Data from Over 3,400 Patients Tested with ThyGenX®/ThyraMIR®
finance.yahoo.com - October 19 at 3:46 AM
Atento (ATTO) & Interpace Diagnostics Group (IDXG) Head to Head ContrastAtento (ATTO) & Interpace Diagnostics Group (IDXG) Head to Head Contrast
www.americanbankingnews.com - October 15 at 8:28 PM
Contrasting Interpace Diagnostics Group (IDXG) & WageWorks (WAGE)Contrasting Interpace Diagnostics Group (IDXG) & WageWorks (WAGE)
www.americanbankingnews.com - October 14 at 8:36 AM
Interpace Diagnostics Announces Increased Reimbursement for ThyGenX®Interpace Diagnostics Announces Increased Reimbursement for ThyGenX®
finance.yahoo.com - October 12 at 6:18 AM
All You Need To Know About Interpace Diagnostics Group Inc’s (IDXG) RisksAll You Need To Know About Interpace Diagnostics Group Inc’s (IDXG) Risks
finance.yahoo.com - October 5 at 9:17 PM
Interpace Diagnostics to Present at The MicroCap Conference on October 5th in New York City at the Essex HouseInterpace Diagnostics to Present at The MicroCap Conference on October 5th in New York City at the Essex House
finance.yahoo.com - September 28 at 8:50 PM
Interpace debuts new lung cancer test that differentiates between recurrent/new disease; shares up 4%Interpace debuts new lung cancer test that differentiates between recurrent/new disease; shares up 4%
seekingalpha.com - September 26 at 10:42 AM
Financial Analysis: Interpace Diagnostics Group (IDXG) versus Cardtronics PLC (CATM)Financial Analysis: Interpace Diagnostics Group (IDXG) versus Cardtronics PLC (CATM)
www.americanbankingnews.com - September 26 at 12:28 AM
Interpace Diagnostics Group (IDXG) vs. Acacia Research Corporation (ACTG) Critical AnalysisInterpace Diagnostics Group (IDXG) vs. Acacia Research Corporation (ACTG) Critical Analysis
www.americanbankingnews.com - September 25 at 10:28 AM
Interpace Diagnostics Announces Expansion into New Clinical Area with Launch of Molecular Lung Cancer TestInterpace Diagnostics Announces Expansion into New Clinical Area with Launch of Molecular Lung Cancer Test
finance.yahoo.com - September 25 at 9:49 AM
Interpace Diagnostics’ CEO Interviewed on The RedChip Money ReportInterpace Diagnostics’ CEO Interviewed on The RedChip Money Report
finance.yahoo.com - September 22 at 1:54 PM
Power Distribution, Inc. Showcases Modular Compact RPP at DCD MexicoPower Distribution, Inc. Showcases Modular Compact RPP at DCD Mexico
feeds.benzinga.com - September 21 at 7:25 AM
Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Audit Committee RequirementsInterpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Audit Committee Requirements
finance.yahoo.com - September 20 at 4:08 PM
Interpace Diagnostics Group, Inc. (IDXG) Sees Large Increase in Short InterestInterpace Diagnostics Group, Inc. (IDXG) Sees Large Increase in Short Interest
www.americanbankingnews.com - September 16 at 2:14 AM
Interpace Diagnostics (IDXG) Appoints Dr. Felice Schnoll-Sussman to BoardInterpace Diagnostics (IDXG) Appoints Dr. Felice Schnoll-Sussman to Board
www.streetinsider.com - September 14 at 11:44 PM
Interpace Diagnostics Announces Appointment of New DirectorInterpace Diagnostics Announces Appointment of New Director
finance.yahoo.com - September 14 at 6:19 AM
BRIEF-Interpace Diagnostics Group Inc - ‍ assigned a new, discreet CPT code to facilitate reimbursement of ThyramirBRIEF-Interpace Diagnostics Group Inc - ‍ assigned a new, discreet CPT code to facilitate reimbursement of Thyramir
www.reuters.com - September 12 at 1:15 AM
Interpace Diagnostics (IDXG) Reports New CPT Code for Reimbursement of Molecular Thyroid TestInterpace Diagnostics (IDXG) Reports New CPT Code for Reimbursement of Molecular Thyroid Test
www.streetinsider.com - September 12 at 1:15 AM
Interpace Diagnostics Announces New CPT Code for Reimbursement of Molecular Thyroid TestInterpace Diagnostics Announces New CPT Code for Reimbursement of Molecular Thyroid Test
finance.yahoo.com - September 11 at 8:13 PM
 Interpace Diagnostics Group, Inc. (IDXG) Given $5.00 Average Price Target by Analysts Interpace Diagnostics Group, Inc. (IDXG) Given $5.00 Average Price Target by Analysts
www.americanbankingnews.com - September 10 at 4:10 PM

SEC Filings

Interpace Diagnostics Group (NASDAQ:IDXG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Interpace Diagnostics Group (NASDAQ:IDXG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Interpace Diagnostics Group (NASDAQ IDXG) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.